Breast Cancer Clinical Trials in Baltimore

Showing 161-180 of 691 trials

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer+7 more

Volastra Therapeutics, Inc.200 participantsStarted Oct 2023

Los Angeles, California, United States • Newport Beach, California, United States • Aurora, Colorado, United States +11 more locations

Active Not RecruitingPhase 2< 1 mile

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05455658

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.

Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8+14 more

University of Washington33 participantsStarted Nov 2022

Baltimore, Maryland, United States • Seattle, Washington, United States • Madison, Wisconsin, United States

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Breast Cancer Trials in Other Cities

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

CARE (Chemotherapy Alopecia REduction)

National Mammography Database

A Study of XMT-1660 in Participants With Solid Tumors

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Other Conditions in Baltimore